Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunesta for Sleep Disturbance and Nightmares in PTSD
NCT00120250Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2005
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of eszopiclone in post-traumatic stress disorder (PTSD), sponsored by Massachusetts General Hospital. Primary endpoints: Short PTSD Rating Interview at 8 weeks and Pittsburgh Sleep Quality Index at 8 weeks. Started Jun 2005; status: completed.
02
Drugs
eszopiclone
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT00120250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120250.